An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms
- PMID: 28475291
- DOI: 10.1002/jcb.26117
An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms
Abstract
The mammalian target of rapamycin (mTOR) is a serine-threonine kinase, which regulates cellular metabolism and growth, and is a validated therapeutic target in various cancers. Recently, OSI-027, a selective ATP competitive inhibitor of mTOR, has been developed. The OSI-027 is an orally bioavailable compound whose anti-cancer activities were observed in various cancer cell lines and tumor xenograft models. The current study is the first attempt to explore the binding mode and the molecular-interactions of OSI-027 with mTOR using molecular docking and (un)binding simulation approaches. The study identified various interacting residues and their extent of involvement in binding was emphasized using different methods. The (un)binding simulation analyses provided snapshots of various phases in OSI-027 binding and identified residues important for binding but away from the catalytic site. Further, to explore a better binder for mTOR among OSI-027 analogs, the virtual screening led to propose an OSI-027 analog with CID: 73294902 as a better inhibitor than the OSI-027 and the native ligand PI-103. The binding mode of the proposed compound is compared with those of OSI-027 and other native inhibitors. The comparison of (un)binding simulation phases of proposed compound with that of OSI-027 revealed that both, bound to the same catalytic site, follow different (un)binding path. Thus, the current study presents computational insights into the OSI-027 mediated inhibition of mTOR kinase and proposed an OSI-027 analog as better mTOR inhibitor, and thus, a good drug for further research in experimental laboratories. J. Cell. Biochem. 118: 4558-4567, 2017. © 2017 Wiley Periodicals, Inc.
Keywords: BINDING POSE; DOCKING; MOLECULAR INTERACTIONS; OSI-027; mTOR.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Discovery and Development of ATP-Competitive mTOR Inhibitors Using Computational Approaches.Curr Pharm Des. 2017 Nov 16;23(29):4321-4331. doi: 10.2174/1381612823666170710150604. Curr Pharm Des. 2017. PMID: 28699534 Review.
-
New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation.J Biomol Struct Dyn. 2017 Dec;35(16):3555-3568. doi: 10.1080/07391102.2016.1262279. Epub 2016 Dec 9. J Biomol Struct Dyn. 2017. PMID: 27860549
-
A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches.J Mol Graph Model. 2015 Nov;62:226-234. doi: 10.1016/j.jmgm.2015.10.005. Epub 2015 Oct 22. J Mol Graph Model. 2015. PMID: 26500112
-
Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma.Comput Biol Chem. 2015 Feb;54:57-65. doi: 10.1016/j.compbiolchem.2015.01.001. Epub 2015 Jan 9. Comput Biol Chem. 2015. PMID: 25625417
-
New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Curr Top Microbiol Immunol. 2010. PMID: 20549474 Review.
Cited by
-
Effects and Mechanisms of Luteolin, a Plant-Based Flavonoid, in the Prevention of Cancers via Modulation of Inflammation and Cell Signaling Molecules.Molecules. 2024 Feb 29;29(5):1093. doi: 10.3390/molecules29051093. Molecules. 2024. PMID: 38474604 Free PMC article. Review.
-
Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase.Front Pharmacol. 2024 Jan 11;14:1231671. doi: 10.3389/fphar.2023.1231671. eCollection 2023. Front Pharmacol. 2024. PMID: 38273823 Free PMC article.
-
Investigating a Library of Flavonoids as Potential Inhibitors of a Cancer Therapeutic Target MEK2 Using in Silico Methods.Int J Mol Sci. 2023 Feb 23;24(5):4446. doi: 10.3390/ijms24054446. Int J Mol Sci. 2023. PMID: 36901876 Free PMC article.
-
An extensive bioinformatics study on the role of mitochondrial solute carrier family 25 in PC and its mechanism behind affecting immune infiltration and tumor energy metabolism.J Transl Med. 2022 Dec 13;20(1):592. doi: 10.1186/s12967-022-03756-2. J Transl Med. 2022. PMID: 36514121 Free PMC article.
-
mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer.Int J Mol Sci. 2022 Oct 18;23(20):12470. doi: 10.3390/ijms232012470. Int J Mol Sci. 2022. PMID: 36293326 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous